Clinical Trials

133 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01590069 2026-04-16

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

DermatologicGenitourinarySarcoma

70 enrolled

Carcinoma, Renal Cell, Melanoma, Sarcoma, Osteosarcoma

NCT03435952 2026-04-16

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

18 enrolled

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT04286386 2026-04-16

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

130 enrolled

Prostate Adenocarcinoma

NCT00918775 2026-04-15

Follow-up After Metastasectomy in Patients With Kidney Cancer

86 enrolled

Carcinoma, Renal Cell

NCT03821792 2026-04-15

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

60 enrolled

Prostatic Neoplasms

NCT04215029 2026-04-15

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

6 enrolled

Prostatic Neoplasms

NCT04396808 2026-04-15

Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer

805 enrolled

Prostatic Neoplasms

NCT04953104 2026-04-15

ARID1A and/or KDM6A Mutation and CXCL13 Expression

6 enrolled

Phase EARLY_PHASE1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05047965 2026-04-15

An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer

65 enrolled

Prostatic Neoplasms

NCT05055843 2026-04-15

Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer

33 enrolled

Prostatic Neoplasms

NCT06049576 2026-04-15

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

31 enrolled

Carcinoma, Renal Cell

NCT05960578 2026-04-14

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

8 enrolled

Prostatic Neoplasms

NCT02346253 2026-04-13

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

146 enrolled

Prostatic Neoplasms

NCT03609216 2026-04-13

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

237 enrolled

Infiltrating Bladder Urothelial Carcinoma

NCT04842890 2026-04-13

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

61 enrolled

Prostatic Neoplasms

NCT06421142 2026-04-13

FAPI and FDG PET/MRI in Diagnosis and Therapy Prediction of Bladder Cancer

80 enrolled

Urinary Bladder Neoplasms

NCT06434649 2026-04-13

Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer

118 enrolled

Prostatic Neoplasms

NCT03361735 2026-04-09

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

25 enrolled 10 charts

Prostate Adenocarcinoma

NCT04985565 2026-04-09

Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer

12 enrolled

Prostatic Neoplasms

NCT07511517 2026-04-09

BladMetrix

500 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Hypersensitivity

NCT00859781 2026-04-08

177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer

55 enrolled 11 charts

Prostatic Neoplasms

NCT03827616 2026-04-08

Moderately Hypofractionated Radiotherapy for Prostate Cancer.

400 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05050084 2026-04-08

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

2,050 enrolled

Prostate Adenocarcinoma

NCT05053152 2026-04-08

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

194 enrolled

Prostatic Neoplasms

NCT05406713 2026-04-08

Pembrolizumab in Muscle-invasive Bladder Cancer

46 enrolled

Carcinoma, Transitional Cell

NCT06303713 2026-04-08

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

37 enrolled

Prostatic Neoplasms

NCT00579514 2026-04-07

Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

BreastGastrointestinalGenitourinaryGynecologicThoracic

21,081 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms

NCT02400944 2026-04-07

Determinants of Bladder Cancer Recurrence Study (The DETER Study)

600 enrolled

Urinary Bladder Neoplasms

NCT03093922 2026-04-07

A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer

32 enrolled

Carcinoma, Transitional Cell

NCT04138628 2026-04-07

TOMBOLA

154 enrolled

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT05079698 2026-04-07

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

29 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT05808608 2026-04-07

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

37 enrolled

Carcinoma, Renal Cell

NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

15 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04709276 2026-04-06

CHAMP

41 enrolled

Prostatic Neoplasms

NCT05703269 2026-04-06

HYPOGRYPHE

BreastCNSDermatologicGenitourinaryThoracic

58 enrolled

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Small Cell Lung Carcinoma

NCT04147806 2026-04-03

PROSINT

31 enrolled

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT04513717 2026-04-03

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

2,753 enrolled

Prostatic Neoplasms

NCT02664883 2026-04-02

Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer

37 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell

NCT03543189 2026-04-01

Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy

44 enrolled

Prostatic Diseases, Prostatic Neoplasms

NCT04300855 2026-04-01

Clinical Trial of Green Tea Catechins in Men on Active Surveillance

115 enrolled

Prostatic Neoplasms

NCT06253845 2026-04-01

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

20 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06734130 2026-04-01

Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer

25 enrolled

Prostatic Neoplasms

NCT03795207 2026-03-31

POSTCARD

96 enrolled

Node; Prostate

NCT04357925 2026-03-31

QoLProstateMQ

304 enrolled

Prostatic Neoplasms

NCT04886986 2026-03-31

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

20 enrolled

Prostatic Neoplasms

NCT05266313 2026-03-31

VITALITE

135 enrolled

Prostatic Neoplasms

NCT03471650 2026-03-30

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

150 enrolled

Prostatic Neoplasms

NCT03436654 2026-03-27

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

102 enrolled